AstraZeneca, BMS Team To Develop Type 2 Diabetes Drug For Japan
This article was originally published in PharmAsia News
Executive Summary
Two multinational drug makers plan to develop a new Type 2 diabetes drug targeted at Japan. AstraZeneca and Bristol-Myers Squibb said they would jointly develop and market dapagliflozin as a once-daily treatment for the disease in Japan and in 2012 in the United States and Europe. AstraZeneca's international sales chief noted that treatment of the disease and associated complications cost Japanese more than $18.4 billion last year alone. Bruno Angelici said the two companies believe dapagliflozin has the potential to reduce the cost and the impact of Type 2 in Japan. (Click here for more